Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01708226
Other study ID # IRB12-001459
Secondary ID 1R34MH095885-01A
Status Completed
Phase Phase 1
First received October 11, 2012
Last updated January 13, 2017
Start date November 2012
Est. completion date August 2016

Study information

Verified date January 2017
Source University of California, Los Angeles
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pediatric Obsessive Compulsive Disorder (OCD) is a chronic, impairing condition that accrues significant concurrent and long-term risk to affected youth. Although empirically supported psychosocial and pharmacological treatments for OCD exist, many children and their families are not able to adequately access these treatments or derive only partial benefit from them. Such findings highlight the importance of developing more effective treatment options which have the potential to be widely accessible to OCD youth.

The investigators are proposing to test a computerized attention modification program, AMP, in six youth with OCD in an open case series to gather information regarding protocol acceptability, feasibility and preliminary efficacy. This phase includes the development and refinement of stimuli selection procedures, behavior avoidance task, EEG protocol, and AMP parameters for use with children.

Following ascertainment of study eligibility, participants will undergo a baseline assessment consisting of a clinical interview, neurocognitive assessments, EEG, attention bias assessment, and self report questionnaires. Study participants will then receive 12 sessions of AMP treatment over the course of three weeks. All youngsters and their families will be reassessed at treatment endpoint (week 4). Participation will take a total of about 24 hours over the course of six weeks. Participants who are treatment responders may be asked to return approximately 3 months after completing treatment for a follow-up assessment.

Preliminary hypotheses: 1) AMP will be acceptable to youth and families and feasible to administer; 2) Youth receiving AMP will demonstrate decreases in threat bias and OCD symptom severity.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date August 2016
Est. primary completion date November 2013
Accepts healthy volunteers No
Gender All
Age group 8 Years to 17 Years
Eligibility Inclusion Criteria:

- Youth ages 8 - 17

- Primary DSM-IV diagnosis of OCD as determined by Anxiety Disorders Interview Schedule (ADIS-IV) Child/Parent version

- Child Yale-Brown Obsessive Compulsive Scale (CYBOCS) score > 15

- Medication free or on stable medication for six weeks prior to study entry

- Informed parental consent and child assent. Parents must agree to their child's participation in this protocol. Parents will be asked to fill out self-report questionnaires and participate in assessments that will provide us with more information about their child, however parents are not considered "participants" within this protocol, as all treatment is targeted toward their child.

Exclusion Criteria:

- DSM-IV depressive disorder, bipolar disorder, PTSD, substance abuse/dependence, conduct disorder, PDD, schizophrenia, or mental retardation

- Concurrent psychosocial treatment for OCD

- IQ < 80

- Youngsters with other comorbid disorders (e.g., anxiety, ADHD, ODD, tic disorder) will be eligible as long as these disorders are secondary to OCD in terms of severity and impairment and do not require immediate treatment initiation.

Study Design


Intervention

Behavioral:
Attention Modification Program
Computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief.

Locations

Country Name City State
United States University of California Los Angeles Los Angeles California

Sponsors (2)

Lead Sponsor Collaborator
University of California, Los Angeles National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Children's Yale-Brown Obsessive Compulsive Scale Change From Pre-Treatment to Post-Treatment pre-treatment (week 0) and post-treatment (week 5)
Secondary Clinical Global Impression-Severity (CGI-S) and Improvement (CGI-I) Scales Change From Pre-Treatment to Post-Treatment pre-treatment (week 0) and post-treatment (week 5)
Secondary Attention Bias Assessment Change from Pre-Treatment to Post-Treatment Computerized assessment of attention bias pre-treatment (week 0) and post-treatment (week 5)
See also
  Status Clinical Trial Phase
Recruiting NCT04631042 - Developing Brain, Impulsivity and Compulsivity
Completed NCT02855580 - Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic
Completed NCT02229903 - An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD N/A
Completed NCT02202915 - CBT for Pediatric OCD: Community Training Pilot N/A
Completed NCT01794156 - Evaluation of a Cognitive Therapy (Inference-based-therapy) for the Treatment of Obsessional Compulsive Disorder N/A
Completed NCT02089984 - Web Based Therapist Training on Cognitive Behavior Therapy for Anxiety Disorders N/A
Completed NCT01348529 - Internet Cognitive Behavior Therapy (CBT) for Obsessive Compulsive Disorder (OCD) N/A
Recruiting NCT00965211 - Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for the Treatment of Tourette Syndrome N/A
Completed NCT01172873 - D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD N/A
Not yet recruiting NCT00743834 - Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Phase 4
Completed NCT00723060 - Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder Phase 4
Completed NCT02421315 - Overlapping Neural Circuits in Pediatric OCD N/A
Completed NCT01981317 - Stepped Care Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder N/A
Completed NCT02194075 - Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Phase 4
Completed NCT01686087 - Attaining and Maintaining Wellness in Obsessive-compulsive Disorder N/A
Completed NCT01331876 - Modification of Cerebral Activity of Obsessive Compulsive Disorder (OCD) Patients During Cognitive and Behavioral Therapy N/A
Terminated NCT00997087 - A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder Phase 2
Completed NCT00533806 - Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder Phase 3
Completed NCT00517244 - Evaluating Parenting Styles and Child Temperament Associated With Child Anxiety Disorders N/A
Completed NCT00169377 - Subthalamic Nucleus (STN) Stimulation and Obsessive-Compulsive Disorder (OCD) Phase 1/Phase 2